shotsy is a technology company.
shotsy has raised $2.0M across 1 funding round.
shotsy has raised $2.0M in total across 1 funding round.
shotsy has raised $2.0M in total across 1 funding round.
shotsy's investors include Adverb Ventures, The Hit Forge, Julian Koh.
Shotsy is a technology company that has developed a first-of-its-kind mobile app designed to help users track their GLP-1 medication usage, including drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. The app serves individuals using these weight-loss and diabetes-related injectable medications by providing an organized, supportive platform to log injections, monitor side effects, and track wellness metrics such as weight and nutrition. Shotsy addresses the problem of manual and cumbersome tracking methods, offering a streamlined digital solution that enhances user adherence and health management. Since its launch, the app has been downloaded over 100,000 times, achieved a revenue run rate of $1 million, and operates profitably with a freemium model that includes a $19.99 annual subscription for premium features[1][2][4][5].
Shotsy was founded by Aja Beckett, a software engineer and serial entrepreneur, who created the app out of personal necessity to better manage her own GLP-1 medication regimen. The idea emerged from her frustration with manual note-taking and the lack of dedicated tools for this growing user base. Beckett’s background includes founding the startup Civil, which focused on improving online dialogue. Shotsy launched approximately eight months before early 2025 and quickly gained traction, with 3,000 downloads in the first 24 hours and strong community support, particularly on Reddit. The company raised $2.25 million in seed funding led by April Underwood of Adverb Ventures, with participation from Coalition Operators, Springbank Collective, and angel investor Esther Dyson, enabling it to expand marketing and grow its team[1][2].
Shotsy rides the wave of increasing adoption of GLP-1 medications, a market UBS projects could exceed 40 million users by 2029. The timing is critical as weight management and diabetes treatments increasingly rely on these injectable drugs, creating a new niche for digital health tools. Shotsy fills a gap in the health tech ecosystem by focusing on a specific medication class with tailored features, unlike broader health trackers. Its success highlights a trend toward specialized, patient-centered digital health solutions that empower users to manage complex treatment regimens effectively. By providing data-driven insights and community support, Shotsy influences how medication adherence and wellness tracking evolve in the chronic disease and weight management sectors[1][2][4].
Shotsy is poised for growth as it leverages its early market leadership and community momentum to expand its user base and feature set. Future trends shaping its journey include the rising prevalence of GLP-1 medication use, increasing consumer demand for personalized health management tools, and potential integration with broader digital health ecosystems. As Shotsy scales, it may deepen its data analytics capabilities and partnerships with healthcare providers or payers, enhancing its role in patient adherence and outcomes. The company’s founder-driven, problem-focused approach and profitable business model position it well to influence the emerging intersection of medication management and digital health innovation[1][2].
shotsy has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2025 | $2.0M Seed | Adverb Ventures, The Hit Forge, Julian Koh |